首页 > 最新文献

Nephro-urology Monthly最新文献

英文 中文
Survival Rate of Hemodialysis Patients: A Competing Risk Analysis Approach 血液透析患者生存率的竞争风险分析方法
Q4 Medicine Pub Date : 2022-09-14 DOI: 10.5812/numonthly-128158
Azita Zafar Mohtashami, B. Hadian, Narges Izadi Meidarsofla
Background: Chronic kidney disease, a global health problem, leads to end-stage kidney disease, whose treatment requires long-term renal replacement therapy. The incidence of hemodialysis patients with end-stage kidney disease is increasing worldwide. The survival rate of hemodialysis patients is crucial for decision-making and planning. Objectives: This study aimed to determine the survival rate of hemodialysis patients and its related factors using the competing risk analysis approach to acquire more precise estimations of survival and mortality of the patients. Methods: This study was primarily based on medical records of hemodialysis patients who started dialysis from January 2011 to December 2017. The end of the study follow-up period was December 2021. The study included 214 eligible patients. Death was regarded as the event of interest, kidney transplantation as the competing risk, and other consequences as censored. We analyzed the data by cumulative incidence functions, Gray’s test, and Fine-Gray regression model using R version 4.1.2 and Stata v.16 at a significance level of 0.05. Results: The median age at the initiation of hemodialysis was 60 years. The risks of death in the first, second, third, fourth, and fifth years were 18.3%, 31.7%, 41.6%, 49.9%, and 60.9%, respectively. In the regression model, age at the initiation of hemodialysis (P-value = 0.000) and education (P-value = 0.000) were associated with mortality. Conclusions: Competing risk estimates of survival analysis of hemodialysis patients are more reliable than conventional approaches (e.g., Kaplan–Meier estimator) for planning and improving interventions and allocating resources. Detection of patients at a younger age and increasing patients' knowledge plays a significant role in improving their survival.
背景:慢性肾脏疾病是一个全球性的健康问题,可导致终末期肾脏疾病,其治疗需要长期肾脏替代治疗。终末期肾病血液透析患者的发病率在世界范围内呈上升趋势。血液透析患者的存活率对决策和计划至关重要。目的:本研究旨在采用竞争风险分析方法确定血液透析患者的生存率及其相关因素,以更准确地估计患者的生存和死亡率。方法:本研究主要基于2011年1月至2017年12月开始透析的血液透析患者的医疗记录。研究随访期于2021年12月结束。该研究包括214名符合条件的患者。死亡被视为值得关注的事件,肾移植被视为竞争风险,其他后果被审查。我们采用累积关联函数、Gray检验和Fine-Gray回归模型对数据进行分析,使用R version 4.1.2和Stata v.16,显著性水平为0.05。结果:开始血液透析的中位年龄为60岁。第一、二、三、四、五年的死亡风险分别为18.3%、31.7%、41.6%、49.9%和60.9%。在回归模型中,开始血液透析的年龄(p值= 0.000)和教育程度(p值= 0.000)与死亡率相关。结论:血液透析患者生存分析的竞争风险估计比传统方法(例如Kaplan-Meier估计)在计划和改进干预措施和分配资源方面更可靠。在更年轻的年龄发现患者并增加患者的知识对提高患者的生存率具有重要作用。
{"title":"Survival Rate of Hemodialysis Patients: A Competing Risk Analysis Approach","authors":"Azita Zafar Mohtashami, B. Hadian, Narges Izadi Meidarsofla","doi":"10.5812/numonthly-128158","DOIUrl":"https://doi.org/10.5812/numonthly-128158","url":null,"abstract":"Background: Chronic kidney disease, a global health problem, leads to end-stage kidney disease, whose treatment requires long-term renal replacement therapy. The incidence of hemodialysis patients with end-stage kidney disease is increasing worldwide. The survival rate of hemodialysis patients is crucial for decision-making and planning. Objectives: This study aimed to determine the survival rate of hemodialysis patients and its related factors using the competing risk analysis approach to acquire more precise estimations of survival and mortality of the patients. Methods: This study was primarily based on medical records of hemodialysis patients who started dialysis from January 2011 to December 2017. The end of the study follow-up period was December 2021. The study included 214 eligible patients. Death was regarded as the event of interest, kidney transplantation as the competing risk, and other consequences as censored. We analyzed the data by cumulative incidence functions, Gray’s test, and Fine-Gray regression model using R version 4.1.2 and Stata v.16 at a significance level of 0.05. Results: The median age at the initiation of hemodialysis was 60 years. The risks of death in the first, second, third, fourth, and fifth years were 18.3%, 31.7%, 41.6%, 49.9%, and 60.9%, respectively. In the regression model, age at the initiation of hemodialysis (P-value = 0.000) and education (P-value = 0.000) were associated with mortality. Conclusions: Competing risk estimates of survival analysis of hemodialysis patients are more reliable than conventional approaches (e.g., Kaplan–Meier estimator) for planning and improving interventions and allocating resources. Detection of patients at a younger age and increasing patients' knowledge plays a significant role in improving their survival.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43865766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Mature Cystic Teratoma of the Retroperitoneum Presenting as a Suprarenal Mass in an Adult Patient: A Case Report 成人腹膜后原发性成熟囊性畸胎瘤表现为肾上肿块一例报告
Q4 Medicine Pub Date : 2022-09-13 DOI: 10.5812/numonthly-126633
Farhood Khaleghi mehr, M. Abolhasani, Yasin Zakeri
Introduction: Primary retroperitoneal mature cystic teratomas (PRPMCT) are uncommon in adults. They typically occur in infants under six months old and young females. So far, some limited case reports have been documented in the literature. This case report presents a rare case of an adult patient with PRPMCT aged over 30 years. Case Presentation: The patient was a 34-year-old female with PRPMCT in the site of the left adrenal gland and abdominal discomfort. Computed tomography (CT) scan revealed a 66 mm hypodense lesion with fat attenuation and calcification in the left retroperitoneum. Laparotomy with resection of the retroperitoneal (RP) lesion was done. Gross examination showed a solid multicystic mass measuring 8x6.5x6 cm. Histopathologic examination revealed a neoplastic tissue composed of mature osseous and cartilaginous tissue associated with stratified squamous epithelium and lumens lined by ciliated columnar epithelium, and the diagnosis was mature cystic teratoma. The patient had an uncomplicated postoperative course without recurrence after seven months of follow-up. Conclusions: PRPMCT in adults is extremely rare. RP metastasis of primary gonadal teratoma and non-functioning adrenal tumors should be excluded first. Due to the diagnostic difficulty of posterior peritoneal teratoma with radiological imaging and its risk of malignancy, surgical resection would be the most effective diagnostic and therapeutic option. Complete resection of the mass is important to judge the existence of immature and solid components that require a long-time follow-up because of the increased risk of malignancy.
引言:原发性腹膜后成熟囊性畸胎瘤(PRPMCT)在成人中并不常见。它们通常发生在六个月以下的婴儿和年轻的女性身上。到目前为止,文献中已经记录了一些有限的病例报告。本病例报告介绍了一例罕见的30岁以上PRPMCT成年患者。病例介绍:患者是一名34岁的女性,左肾上腺部位有PRPMCT,腹部不适。计算机断层扫描显示左腹膜后有66毫米的低密度病变,伴有脂肪衰减和钙化。腹膜后病变切除术。大体检查显示一个大小为8x6.5x6 cm的固体多囊质肿块。组织病理学检查显示肿瘤组织由成熟的骨和软骨组织组成,与复层鳞状上皮和纤毛柱状上皮排列的管腔有关,诊断为成熟囊性畸胎瘤。经过7个月的随访,患者术后无复发。结论:成人PRPMCT极为罕见。应首先排除原发性性腺畸胎瘤和无功能肾上腺肿瘤的RP转移。由于腹膜后畸胎瘤的影像学诊断困难及其恶性风险,手术切除将是最有效的诊断和治疗选择。完全切除肿块对于判断是否存在未成熟和坚固的成分很重要,因为恶性肿瘤的风险增加,这些成分需要长期随访。
{"title":"Primary Mature Cystic Teratoma of the Retroperitoneum Presenting as a Suprarenal Mass in an Adult Patient: A Case Report","authors":"Farhood Khaleghi mehr, M. Abolhasani, Yasin Zakeri","doi":"10.5812/numonthly-126633","DOIUrl":"https://doi.org/10.5812/numonthly-126633","url":null,"abstract":"Introduction: Primary retroperitoneal mature cystic teratomas (PRPMCT) are uncommon in adults. They typically occur in infants under six months old and young females. So far, some limited case reports have been documented in the literature. This case report presents a rare case of an adult patient with PRPMCT aged over 30 years. Case Presentation: The patient was a 34-year-old female with PRPMCT in the site of the left adrenal gland and abdominal discomfort. Computed tomography (CT) scan revealed a 66 mm hypodense lesion with fat attenuation and calcification in the left retroperitoneum. Laparotomy with resection of the retroperitoneal (RP) lesion was done. Gross examination showed a solid multicystic mass measuring 8x6.5x6 cm. Histopathologic examination revealed a neoplastic tissue composed of mature osseous and cartilaginous tissue associated with stratified squamous epithelium and lumens lined by ciliated columnar epithelium, and the diagnosis was mature cystic teratoma. The patient had an uncomplicated postoperative course without recurrence after seven months of follow-up. Conclusions: PRPMCT in adults is extremely rare. RP metastasis of primary gonadal teratoma and non-functioning adrenal tumors should be excluded first. Due to the diagnostic difficulty of posterior peritoneal teratoma with radiological imaging and its risk of malignancy, surgical resection would be the most effective diagnostic and therapeutic option. Complete resection of the mass is important to judge the existence of immature and solid components that require a long-time follow-up because of the increased risk of malignancy.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46565594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dialysis During the COVID-19 Pandemic: Experiences from 4 Dialysis Centers in Iran 新冠肺炎大流行期间的透析:伊朗4个透析中心的经验
Q4 Medicine Pub Date : 2022-07-26 DOI: 10.5812/numonthly-127290
Z. Rostami, Farzaneh Futuhi, E. Nemati, Azam Soleimani Najafabadi, M. Javanbakht, M. Ebrahimi, Bentolhoda Beyram, B. Einollahi
Background: Despite all of the research on the risk factors for severe COVID-19, there are still many unknowns about the course of COVID-19 in various populations. Inevitable exposure of dialysis patients, one of the more vulnerable groups for infectious diseases, to COVID-19 concerns many researchers. Furthermore, studies on the mortality rate and risk factors regarding dialysis patients are somewhat inconsistent. Also, it has been suggested that factors such as ethnicity can contribute to that matter. Objectives: We aimed to evaluate the mortality rate of dialysis patients who contracted COVID-19 in the Iranian population. Methods: In this cross-sectional study, we presented the experiences of 4 dialysis centers with a total of 309 dialysis patients (Tehran, Iran) during the COVID-19 pandemic to assess the mortality rate and associated risk factors. Results: Among 309 dialysis patients, 58 patients contracted the disease, and the total mortality rate in this study was 41%. It was observed that although the guidelines for screening patients were similar in these 4 centers, the centers with regular COVID-19 screening for staff members had much lower mortality and infection rate. The most common symptoms in patients were fever, dry cough, and chills. Furthermore, comorbidities such as diabetes can also increase the risk of mortality. Conclusions: This study, along with other studies, can be utilized in developing guidelines for dialysis centers in the COVID-19 pandemic and future pandemics.
背景:尽管对严重新冠肺炎的危险因素进行了所有研究,但对不同人群中新冠肺炎的病程仍有许多未知之处。许多研究人员担心,透析患者不可避免地接触新冠肺炎,这是传染病最易感染的群体之一。此外,关于透析患者的死亡率和危险因素的研究有些不一致。此外,有人认为,种族等因素也可能导致这一问题。目的:我们旨在评估伊朗人群中感染新冠肺炎的透析患者的死亡率。方法:在这项横断面研究中,我们介绍了新冠肺炎大流行期间4个透析中心共309名透析患者(伊朗德黑兰)的经验,以评估死亡率和相关风险因素。结果:在309名透析患者中,58名患者感染了这种疾病,本研究的总死亡率为41%。据观察,尽管这4个中心的患者筛查指南相似,但定期对工作人员进行新冠肺炎筛查的中心的死亡率和感染率要低得多。患者最常见的症状是发烧、干咳和发冷。此外,糖尿病等合并症也会增加死亡率。结论:本研究与其他研究可用于制定新冠肺炎大流行和未来大流行中透析中心的指南。
{"title":"Dialysis During the COVID-19 Pandemic: Experiences from 4 Dialysis Centers in Iran","authors":"Z. Rostami, Farzaneh Futuhi, E. Nemati, Azam Soleimani Najafabadi, M. Javanbakht, M. Ebrahimi, Bentolhoda Beyram, B. Einollahi","doi":"10.5812/numonthly-127290","DOIUrl":"https://doi.org/10.5812/numonthly-127290","url":null,"abstract":"Background: Despite all of the research on the risk factors for severe COVID-19, there are still many unknowns about the course of COVID-19 in various populations. Inevitable exposure of dialysis patients, one of the more vulnerable groups for infectious diseases, to COVID-19 concerns many researchers. Furthermore, studies on the mortality rate and risk factors regarding dialysis patients are somewhat inconsistent. Also, it has been suggested that factors such as ethnicity can contribute to that matter. Objectives: We aimed to evaluate the mortality rate of dialysis patients who contracted COVID-19 in the Iranian population. Methods: In this cross-sectional study, we presented the experiences of 4 dialysis centers with a total of 309 dialysis patients (Tehran, Iran) during the COVID-19 pandemic to assess the mortality rate and associated risk factors. Results: Among 309 dialysis patients, 58 patients contracted the disease, and the total mortality rate in this study was 41%. It was observed that although the guidelines for screening patients were similar in these 4 centers, the centers with regular COVID-19 screening for staff members had much lower mortality and infection rate. The most common symptoms in patients were fever, dry cough, and chills. Furthermore, comorbidities such as diabetes can also increase the risk of mortality. Conclusions: This study, along with other studies, can be utilized in developing guidelines for dialysis centers in the COVID-19 pandemic and future pandemics.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46515196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Electrolyte Imbalance and COVID-19 Severity in Hospitalized Patients 住院患者电解质失衡与COVID-19严重程度的关系
Q4 Medicine Pub Date : 2022-07-13 DOI: 10.5812/numonthly-128085
M. Miri, Shaghayegh Badriahmadi, A. Shamshirian, AmirAli Moodi Ghalibaf, Mahnaz Mozdourian
Background: Various risk factors have been proposed for severe coronavirus disease 2019 (COVID-19); nonetheless, the prognostic role of serum electrolytes has not been widely studied. Objectives: The present study aimed to identify the potential prognostic role of electrolyte imbalance in hospitalized COVID-19 patients. Methods: This retrospective study was conducted in Imam Reza Hospital, Mashhad, Iran. The medical records of all COVID-19 patients admitted to the emergency department from May to August 2020 were evaluated. Demographic data and clinical findings upon admission were collected. Disease severity, lung involvement severity on imaging, inflammatory serum biomarkers, admission to the intensive care unit, and serum levels of sodium, potassium, magnesium, calcium (corrected by serum albumin level), and phosphorus were documented. Results: Most patients (60%) were male, and the mean age of the total population was 58.87 ± 1.82 years. Severe COVID-19 was detected in most cases (94.9%) who were significantly older (P = 0.037), had hypertension (P = 0.032), ischemic heart disease (P = 0.033), and higher serum urea (P = 0.001) and serum potassium (P < 0.001). Patients with poor prognosis based on computed tomography (CT) scores had significantly higher serum urea (P = 0.002) and magnesium (P = 0.035) than patients with good prognosis, while serum calcium was significantly higher in the latter group (P = 0.007). Furthermore, there was a significant relationship between COVID-19 severity and serum potassium (P < 0.001). Conclusions: Abnormal serum electrolytes are correlated with COVID-19 severity. Moreover, serum potassium level is a predictor of severe disease.
背景:已提出2019年严重冠状病毒病(新冠肺炎)的各种风险因素;尽管如此,血清电解质对预后的作用尚未得到广泛研究。目的:本研究旨在确定新冠肺炎住院患者电解质失衡的潜在预后作用。方法:本回顾性研究在伊朗马什哈德伊玛目礼萨医院进行。对2020年5月至8月急诊科收治的所有新冠肺炎患者的病历进行了评估。收集入院时的人口学数据和临床发现。记录了疾病严重程度、影像学上肺部受累的严重程度、炎症血清生物标志物、进入重症监护室以及血清钠、钾、镁、钙(通过血清白蛋白水平校正)和磷水平。结果:大多数患者(60%)为男性,总人群的平均年龄为58.87±1.82岁。大多数病例(94.9%)检测到严重的新冠肺炎,这些病例年龄较大(P=0.037)、患有高血压(P=0.032)、缺血性心脏病(P=0.033),以及更高的血清尿素(P=0.001)和血清钾(P<0.001)。根据计算机断层扫描(CT)评分,预后较差的患者的血清尿素和镁(P=0.005)显著高于预后良好的患者,而后一组的血清钙显著高于预后好的患者(P=0.007)。此外,结论:血清电解质异常与新冠肺炎严重程度相关。此外,血清钾水平是严重疾病的预测指标。
{"title":"Electrolyte Imbalance and COVID-19 Severity in Hospitalized Patients","authors":"M. Miri, Shaghayegh Badriahmadi, A. Shamshirian, AmirAli Moodi Ghalibaf, Mahnaz Mozdourian","doi":"10.5812/numonthly-128085","DOIUrl":"https://doi.org/10.5812/numonthly-128085","url":null,"abstract":"Background: Various risk factors have been proposed for severe coronavirus disease 2019 (COVID-19); nonetheless, the prognostic role of serum electrolytes has not been widely studied. Objectives: The present study aimed to identify the potential prognostic role of electrolyte imbalance in hospitalized COVID-19 patients. Methods: This retrospective study was conducted in Imam Reza Hospital, Mashhad, Iran. The medical records of all COVID-19 patients admitted to the emergency department from May to August 2020 were evaluated. Demographic data and clinical findings upon admission were collected. Disease severity, lung involvement severity on imaging, inflammatory serum biomarkers, admission to the intensive care unit, and serum levels of sodium, potassium, magnesium, calcium (corrected by serum albumin level), and phosphorus were documented. Results: Most patients (60%) were male, and the mean age of the total population was 58.87 ± 1.82 years. Severe COVID-19 was detected in most cases (94.9%) who were significantly older (P = 0.037), had hypertension (P = 0.032), ischemic heart disease (P = 0.033), and higher serum urea (P = 0.001) and serum potassium (P < 0.001). Patients with poor prognosis based on computed tomography (CT) scores had significantly higher serum urea (P = 0.002) and magnesium (P = 0.035) than patients with good prognosis, while serum calcium was significantly higher in the latter group (P = 0.007). Furthermore, there was a significant relationship between COVID-19 severity and serum potassium (P < 0.001). Conclusions: Abnormal serum electrolytes are correlated with COVID-19 severity. Moreover, serum potassium level is a predictor of severe disease.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41618038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
A Comparison Between the Effects of Calcium Acetate and Sevelamer Carbonate on Progression of Aortic Vascular Calcification in Patients with Chronic Kidney Disease Stages 4 and 5 醋酸钙与碳酸西维拉默对慢性肾病4期和5期主动脉血管钙化进展影响的比较
Q4 Medicine Pub Date : 2022-07-12 DOI: 10.5812/numonthly-120721
H. Verma, S. Sunder, B. Sharma, N. Sharma, Rashi Verma
Background: Calcium-based and non-calcium-based phosphate binders are frequently used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). Objectives: This study aimed to compare the effects of calcium acetate and sevelamer carbonate on the progression of aortic vascular calcification in patients with CKD stages 4 and 5. Methods: This was an open-label randomized prospective comparative study, in which the participants encompassed both male and female patients with ambulatory hyperphosphatemic CKD stages 4 and 5 aged above 18 years. One hundred fifty patients with CKD stages 4 and 5 were screened for Aortic vascular calcification using digital X-ray lumbar spine and multi-slice CT scan, of whom fifty patients with vascular calcification were selected and randomly assigned into two groups. The participants were then serially studied for the effects of phosphate binders on the progression of vascular calcification over one year. One group was prescribed calcium acetate, and the other group was prescribed sevelamer carbonate. Results: Fifty hyperphosphatemic CKD patients with a mean age of 57 years were randomly assigned into two groups. There was no statistically significant difference between the two groups; however, the patients assigned to the sevelamer group were older and higher aortic calcification index (ACI) (P = 0.035) and Kauppila scores (P = 0.04), and elevated serum calcium (P = 0.04), Ca X PO4 (P = 0.006), and vitamin D. In calcium acetate-treated patients, the mean ACI increased significantly during six months and one year; however, the increase was not significant in the sevelamer group. Serum cholesterol, serum triglycerides, serum iPTH level, and the inflammatory markers of atherosclerosis high sensitivity of C-reactive protein (hs-CRP), interleukin-6 (IL-6) (hs-CRP, IL-6) decreased significantly in the sevelamer group. Conclusions: The prevalence of vascular (abdominal aortic) calcification in pre-ESRD (CKD stage 4 and 5) patients was 75%. Abdominal aortic calcification increased significantly in calcium acetate-treated patients during six months and one year; however, the progression was not significant regarding sevelamer. Because of its pleiotropic properties, sevelamer is more effective and consistent in retarding the progression of vascular calcification than calcium acetate in patients with CKD stages 4 and 5.
背景:钙基和非钙基磷酸盐结合剂经常用于治疗慢性肾脏疾病(CKD)患者的高磷血症。目的:本研究旨在比较醋酸钙和碳酸西维拉默对CKD 4期和5期患者主动脉血管钙化进展的影响。方法:这是一项开放标签随机前瞻性比较研究,参与者包括18岁以上的动态高磷血症CKD 4期和5期男性和女性患者。采用腰椎数字x线及多层CT扫描对150例CKD 4期和5期患者进行主动脉血管钙化筛查,其中选择50例血管钙化患者,随机分为两组。随后,研究人员对参与者进行了为期一年的磷酸盐结合剂对血管钙化进展的影响的连续研究。一组服用醋酸钙,另一组服用碳酸七维拉默。结果:50例平均年龄57岁的高磷血症CKD患者随机分为两组。两组间差异无统计学意义;然而,sevelamer组患者年龄较大,主动脉钙化指数(ACI) (P = 0.035)和Kauppila评分(P = 0.04)较高,血清钙(P = 0.04)、Ca X PO4 (P = 0.006)和维生素d升高。在醋酸钙治疗的患者中,平均ACI在6个月和1年内显著升高;然而,sevelamer组的增加并不显著。血清胆固醇、血清甘油三酯、血清iPTH水平及动脉粥样硬化高敏炎症标志物c -反应蛋白(hs-CRP)、白细胞介素-6 (hs-CRP, IL-6)均显著降低。结论:esrd前(CKD 4期和5期)患者血管(腹主动脉)钙化的发生率为75%。醋酸钙治疗6个月和1年的患者腹主动脉钙化显著增加;然而,sevelamer的进展并不显著。由于其多效性,在CKD 4期和5期患者中,sevelamer比醋酸钙更有效和一致地延缓血管钙化的进展。
{"title":"A Comparison Between the Effects of Calcium Acetate and Sevelamer Carbonate on Progression of Aortic Vascular Calcification in Patients with Chronic Kidney Disease Stages 4 and 5","authors":"H. Verma, S. Sunder, B. Sharma, N. Sharma, Rashi Verma","doi":"10.5812/numonthly-120721","DOIUrl":"https://doi.org/10.5812/numonthly-120721","url":null,"abstract":"Background: Calcium-based and non-calcium-based phosphate binders are frequently used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). Objectives: This study aimed to compare the effects of calcium acetate and sevelamer carbonate on the progression of aortic vascular calcification in patients with CKD stages 4 and 5. Methods: This was an open-label randomized prospective comparative study, in which the participants encompassed both male and female patients with ambulatory hyperphosphatemic CKD stages 4 and 5 aged above 18 years. One hundred fifty patients with CKD stages 4 and 5 were screened for Aortic vascular calcification using digital X-ray lumbar spine and multi-slice CT scan, of whom fifty patients with vascular calcification were selected and randomly assigned into two groups. The participants were then serially studied for the effects of phosphate binders on the progression of vascular calcification over one year. One group was prescribed calcium acetate, and the other group was prescribed sevelamer carbonate. Results: Fifty hyperphosphatemic CKD patients with a mean age of 57 years were randomly assigned into two groups. There was no statistically significant difference between the two groups; however, the patients assigned to the sevelamer group were older and higher aortic calcification index (ACI) (P = 0.035) and Kauppila scores (P = 0.04), and elevated serum calcium (P = 0.04), Ca X PO4 (P = 0.006), and vitamin D. In calcium acetate-treated patients, the mean ACI increased significantly during six months and one year; however, the increase was not significant in the sevelamer group. Serum cholesterol, serum triglycerides, serum iPTH level, and the inflammatory markers of atherosclerosis high sensitivity of C-reactive protein (hs-CRP), interleukin-6 (IL-6) (hs-CRP, IL-6) decreased significantly in the sevelamer group. Conclusions: The prevalence of vascular (abdominal aortic) calcification in pre-ESRD (CKD stage 4 and 5) patients was 75%. Abdominal aortic calcification increased significantly in calcium acetate-treated patients during six months and one year; however, the progression was not significant regarding sevelamer. Because of its pleiotropic properties, sevelamer is more effective and consistent in retarding the progression of vascular calcification than calcium acetate in patients with CKD stages 4 and 5.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41587929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Sodium Alterations in Children with Primary Monosymptomatic Nocturnal Enuresis Using Desmopressin 应用Desmopressin治疗原发性单症状夜间遗尿患儿血清钠的变化
Q4 Medicine Pub Date : 2022-06-27 DOI: 10.5812/numonthly-126626
E. Valavi, A. Nickavar, Parisa Amoori, Sadrodin Raiszadeh
Background: Hyponatremia/water intoxication has been considered a rare but serious complication of desmopressin (DDAVP) for the treatment of primary monosymptomatic nocturnal enuresis (PMNE). Objectives: This study aimed to identify the incidence and risk factors of serum sodium (Na) alterations in children with PMNE treated with oral or intranasal DDAVP. Methods: A total of 201 patients with PMNE were evaluated in 2 groups using intranasal (n = 127) or oral DDAVP (n = 74) for approximately 6 months. Treatment efficacy was defined as a more than 50% decrease in wet nights after 1 month of treatment. Serum Na was measured before, during, and after treatment in all patients. Predisposing factors of serum Na disturbance were evaluated concomitantly. Results: The mean age of patients was 8.8 ± 2.6 (5 - 17.5) years, and males outnumbered females (M/F = 1.68). Treatment efficacy was 100% in 93 (46.2%), and > 90% in 157 (78.1%) cases. Oral DDAVP had significantly more therapeutic effects than intranasal treatment (P = 0.024). However, serum Na had no significant difference between the 2 groups (P = 0.52). Hyponatremia occurred in 7 (3.5%) patients (3 in oral treatment and 4 in intranasal treatment; P = 0.73) with no significant correlation to age, gender, body weight, frequency of enuresis, and initial serum Na. However, decreased serum Na > 5 mEq/L was a significant risk factor for the prediction of hyponatremia in our patients (P < 0.001). Conclusions: Oral DDAVP had more therapeutic effects than intranasal treatment for the treatment of PMNE. Serum Na had no significant alteration in both oral and intranasal treatments, and hyponatremia was a rare complication of DDAVP, which occurred significantly in children with a > 5-mEq/L decrease of initial serum Na concentration. As a suggestion, monitoring serum Na is not an essential follow-up in asymptomatic patients in DDAVP treatment.
背景:低钠血症/水中毒被认为是去氨加压素(DDAVP)治疗原发性单症状夜间遗尿(PMNE)的一种罕见但严重的并发症。目的:本研究旨在确定口服或鼻内DDAVP治疗PMNE儿童血清钠(Na)变化的发生率和危险因素。方法:共有201名PMNE患者分为两组,使用鼻内(n=127)或口服DDAVP(n=74)评估约6个月。治疗效果被定义为治疗1个月后湿夜减少50%以上。所有患者在治疗前、治疗中和治疗后均测量血清Na。同时评估血清钠紊乱的易发因素。结果:患者的平均年龄为8.8±2.6(5-17.5)岁,男性多于女性(M/F=1.68)。93例(46.2%)的疗效为100%,157例(78.1%)的疗效大于90%。口服DDAVP的治疗效果明显高于鼻内治疗(P=0.024)。然而,血清Na在两组之间没有显著差异(P=0.52)。7名(3.5%)患者出现低钠血症(3名口服治疗,4名鼻内治疗;P=0.73),与年龄、性别、体重、遗尿频率和初始血清Na没有显著相关性。然而,血清Na>5mEq/L的降低是预测本组患者低钠血症的重要危险因素(P<0.001)。结论:口服DDAVP治疗PMNE的疗效优于鼻内治疗。血清钠在口服和鼻内治疗中均无显著变化,低钠血症是DDAVP的一种罕见并发症,在初始血清钠浓度降低>5-mEq/L的儿童中显著发生。作为一项建议,监测血清钠不是DDAVP治疗中无症状患者的必要随访。
{"title":"Serum Sodium Alterations in Children with Primary Monosymptomatic Nocturnal Enuresis Using Desmopressin","authors":"E. Valavi, A. Nickavar, Parisa Amoori, Sadrodin Raiszadeh","doi":"10.5812/numonthly-126626","DOIUrl":"https://doi.org/10.5812/numonthly-126626","url":null,"abstract":"Background: Hyponatremia/water intoxication has been considered a rare but serious complication of desmopressin (DDAVP) for the treatment of primary monosymptomatic nocturnal enuresis (PMNE). Objectives: This study aimed to identify the incidence and risk factors of serum sodium (Na) alterations in children with PMNE treated with oral or intranasal DDAVP. Methods: A total of 201 patients with PMNE were evaluated in 2 groups using intranasal (n = 127) or oral DDAVP (n = 74) for approximately 6 months. Treatment efficacy was defined as a more than 50% decrease in wet nights after 1 month of treatment. Serum Na was measured before, during, and after treatment in all patients. Predisposing factors of serum Na disturbance were evaluated concomitantly. Results: The mean age of patients was 8.8 ± 2.6 (5 - 17.5) years, and males outnumbered females (M/F = 1.68). Treatment efficacy was 100% in 93 (46.2%), and > 90% in 157 (78.1%) cases. Oral DDAVP had significantly more therapeutic effects than intranasal treatment (P = 0.024). However, serum Na had no significant difference between the 2 groups (P = 0.52). Hyponatremia occurred in 7 (3.5%) patients (3 in oral treatment and 4 in intranasal treatment; P = 0.73) with no significant correlation to age, gender, body weight, frequency of enuresis, and initial serum Na. However, decreased serum Na > 5 mEq/L was a significant risk factor for the prediction of hyponatremia in our patients (P < 0.001). Conclusions: Oral DDAVP had more therapeutic effects than intranasal treatment for the treatment of PMNE. Serum Na had no significant alteration in both oral and intranasal treatments, and hyponatremia was a rare complication of DDAVP, which occurred significantly in children with a > 5-mEq/L decrease of initial serum Na concentration. As a suggestion, monitoring serum Na is not an essential follow-up in asymptomatic patients in DDAVP treatment.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43491231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prevalence and Risk Factors for Urinary Tract Infection in Kidney Transplant Recipients in the First Year After Transplantation 肾移植受者移植后第一年尿路感染的患病率及危险因素
Q4 Medicine Pub Date : 2022-06-22 DOI: 10.5812/numonthly-116629
Vida Sarmadi, Sahar Vahdat, S. Shahidi, A. Atapour, S. Hosseini
Background: End-stage renal disease (ESRD) needs replacement therapy and most often, kidney transplantation is the best therapeutic option. Urinary tract infection (UTI) is one of the most important complications after renal transplantation that affects transplantation outcomes. Objectives: This study aimed to define the incidence rate, UTI risk factors among kidney transplant recipients, and causative organism of UTI and their antibiotic susceptibility. Methods: In this cross-sectional study, we collected clinical, demographic, and laboratory data from 268 transplant recipients in Ali-Asghar Hospital from 2011 - 2018. Data collected from patients were analyzed with SPSS software version 25. Results: According to the results, 50 (18.7%) had UTI in the first year after renal transplantation. Female gender and underlying cause of renal failure were predisposing factors for UTI. The most common causative organism was Escherichia coli (58.4%). The antibiotic susceptibility results showed nitrofurantoin and meropenem as the most effective antibiotics for Escherichia coli. Conclusions: The UTI was more common in women and patients with analgesic nephropathy and lupus nephritis. The most common causative organism was E. coli and meropenem and nitrofurantoin were the most effective drug choices.
背景:终末期肾病(ESRD)需要替代治疗,肾移植通常是最好的治疗选择。尿路感染(UTI)是肾移植术后影响移植预后的重要并发症之一。目的:本研究旨在明确肾移植受者尿路感染发生率、尿路感染危险因素、尿路感染病原菌及其抗生素敏感性。方法:在这项横断面研究中,我们收集了2011年至2018年Ali-Asghar医院268名移植受者的临床、人口统计学和实验室数据。采用SPSS软件25对患者数据进行分析。结果:50例(18.7%)肾移植术后1年内发生尿路感染。女性性别和肾功能衰竭的潜在原因是尿路感染的易感因素。最常见的病原菌为大肠杆菌(58.4%)。药敏结果显示,呋喃妥因和美罗培南是对大肠杆菌最有效的抗生素。结论:尿路感染在女性及疼痛性肾病和狼疮性肾炎患者中更为常见。最常见的病原菌是大肠杆菌,美罗培南和呋喃妥英是最有效的药物。
{"title":"The Prevalence and Risk Factors for Urinary Tract Infection in Kidney Transplant Recipients in the First Year After Transplantation","authors":"Vida Sarmadi, Sahar Vahdat, S. Shahidi, A. Atapour, S. Hosseini","doi":"10.5812/numonthly-116629","DOIUrl":"https://doi.org/10.5812/numonthly-116629","url":null,"abstract":"Background: End-stage renal disease (ESRD) needs replacement therapy and most often, kidney transplantation is the best therapeutic option. Urinary tract infection (UTI) is one of the most important complications after renal transplantation that affects transplantation outcomes. Objectives: This study aimed to define the incidence rate, UTI risk factors among kidney transplant recipients, and causative organism of UTI and their antibiotic susceptibility. Methods: In this cross-sectional study, we collected clinical, demographic, and laboratory data from 268 transplant recipients in Ali-Asghar Hospital from 2011 - 2018. Data collected from patients were analyzed with SPSS software version 25. Results: According to the results, 50 (18.7%) had UTI in the first year after renal transplantation. Female gender and underlying cause of renal failure were predisposing factors for UTI. The most common causative organism was Escherichia coli (58.4%). The antibiotic susceptibility results showed nitrofurantoin and meropenem as the most effective antibiotics for Escherichia coli. Conclusions: The UTI was more common in women and patients with analgesic nephropathy and lupus nephritis. The most common causative organism was E. coli and meropenem and nitrofurantoin were the most effective drug choices.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43428661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of Citrate Dialysis in Patients with Contraindication for Heparin in a Limited-Resource Setting 在资源有限的情况下,柠檬酸透析在肝素禁忌症患者中的应用
Q4 Medicine Pub Date : 2022-06-22 DOI: 10.5812/numonthly-124164
Rajaram Jagdale, Alan Almeida, J. Kothari, R. Sirsat, Supriya Surwase, Dixon Thomas
Background: Hemodialysis among critical care patients with acute kidney injury (AKI) is challenging, especially if heparin is contraindicated. Objectives: This study assessed the utility of citrate dialysis for such patients in a limited-resource setting. Methods: In this prospective study, patients were divided into group A (heparin-free saline flush dialysis), group B (heparin-free citrate dialysis without flushing), and group C (heparin-free citrate dialysis with flushing). The subjects underwent completed sustained low-efficiency daily dialysis (blood flow = 150 mL/minute, dialysate = 300 mL/minute) or intermittent hemodialysis (blood flow = 250 mL/minute, dialysate flow = 500 mL/minute). Statistical tests using SPSS software (version 26) were used to determine safety and effectiveness differences. Results: Among 25 patients studied with multiple hemodialysis sessions, blood flow and dialysate flow were observed to be better in heparin-free citrate dialysis with flushing. There were further advantages of lesser dialyzer clotting and more reuse of dialyzers. Metabolic differences were insignificant. Heparin-free citrate dialysis with or without flushing was equally effective and safe, compared to heparin-free saline flush dialysis, in patients with or without liver impairment. Conclusions: Citrate dialysis is observed to be a safe and effective alternative to heparin-free saline flushing dialysis in intensive care unit patients with AKI. More such studies are required in limited-resource settings to utilize citrate dialysis in patients with heparin contraindication.
背景:急性肾损伤(AKI)重症监护患者的血液透析具有挑战性,尤其是在肝素禁忌的情况下。目的:本研究评估了在资源有限的情况下柠檬酸盐透析对此类患者的效用。方法:在这项前瞻性研究中,患者被分为A组(无肝素盐水冲洗透析)、B组(无冲洗的无肝素柠檬酸盐透析)和C组(带冲洗的不含肝素柠檬酸钠透析)。受试者接受了完整的持续低效每日透析(血流量=150 mL/分钟,透析液=300 mL/分钟)或间歇性血液透析(血流速=250 mL/分,透析液流量=500 mL/分)。使用SPSS软件(版本26)进行统计测试,以确定安全性和有效性差异。结果:在25名接受多次血液透析的患者中,观察到无肝素柠檬酸盐冲洗透析的血流量和透析液流量更好。还有透析器凝结较少和透析器重复使用较多的优点。代谢差异不显著。在有或无肝损伤的患者中,与无肝素盐水冲洗透析相比,不含肝素的柠檬酸盐透析加或不加冲洗同样有效和安全。结论:在重症监护室AKI患者中,柠檬酸盐透析是一种安全有效的替代无肝素盐水冲洗透析的方法。在资源有限的情况下,需要更多这样的研究来对肝素禁忌症患者进行柠檬酸盐透析。
{"title":"Utility of Citrate Dialysis in Patients with Contraindication for Heparin in a Limited-Resource Setting","authors":"Rajaram Jagdale, Alan Almeida, J. Kothari, R. Sirsat, Supriya Surwase, Dixon Thomas","doi":"10.5812/numonthly-124164","DOIUrl":"https://doi.org/10.5812/numonthly-124164","url":null,"abstract":"Background: Hemodialysis among critical care patients with acute kidney injury (AKI) is challenging, especially if heparin is contraindicated. Objectives: This study assessed the utility of citrate dialysis for such patients in a limited-resource setting. Methods: In this prospective study, patients were divided into group A (heparin-free saline flush dialysis), group B (heparin-free citrate dialysis without flushing), and group C (heparin-free citrate dialysis with flushing). The subjects underwent completed sustained low-efficiency daily dialysis (blood flow = 150 mL/minute, dialysate = 300 mL/minute) or intermittent hemodialysis (blood flow = 250 mL/minute, dialysate flow = 500 mL/minute). Statistical tests using SPSS software (version 26) were used to determine safety and effectiveness differences. Results: Among 25 patients studied with multiple hemodialysis sessions, blood flow and dialysate flow were observed to be better in heparin-free citrate dialysis with flushing. There were further advantages of lesser dialyzer clotting and more reuse of dialyzers. Metabolic differences were insignificant. Heparin-free citrate dialysis with or without flushing was equally effective and safe, compared to heparin-free saline flush dialysis, in patients with or without liver impairment. Conclusions: Citrate dialysis is observed to be a safe and effective alternative to heparin-free saline flushing dialysis in intensive care unit patients with AKI. More such studies are required in limited-resource settings to utilize citrate dialysis in patients with heparin contraindication.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45448850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-year-old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report 15岁患者接种第二剂BBIBP-CorV(国药)COVID-19疫苗后发生抗中性粒细胞胞浆抗体(ANCA)相关性肾小球肾炎1例
Q4 Medicine Pub Date : 2022-06-01 DOI: 10.5812/numonthly-127124
Elham Ramezanzade, Reyhane Ghanbari, Tina Yazdanipour
Introduction: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of multisystemic autoimmune diseases that can involve organs such as kidneys and respiratory tracts. Since the initiation of COVID-19 vaccines, there have been few cases of antineutrophil cytoplasmic antibody (ANCA) glomerulonephritis development after receiving vaccine doses. Case Presentation: This report describes a 15-year-old man who has developed ANCA-associated glomerulonephritis (AAGN) after receiving the second dose of BBIBP-CorV (Sinopharm) COVID-19 vaccine. Conclusions: Development of AAGN after both natural SARS-CoV-2 infection and following other vaccinations raises the question of the possible causality between the two. Considering the widespread use of COVID-19 vaccines, it is highly important to investigate their possible side effects.
引言:抗中性粒细胞胞浆自身抗体(ANCA)相关血管炎(AAV)是一组多系统自身免疫性疾病,可累及肾脏和呼吸道等器官。自新冠肺炎疫苗接种以来,接种疫苗后出现抗中性粒细胞胞质抗体(ANCA)肾小球肾炎的病例很少。病例介绍:本报告描述了一名15岁男子在接种第二剂BBIBP-CorV(国药集团)新冠肺炎疫苗后出现ANCA相关肾小球肾炎(AAGN)。结论:自然感染严重急性呼吸系统综合征冠状病毒2型和接种其他疫苗后AAGN的发展提出了两者之间可能的因果关系问题。考虑到新冠肺炎疫苗的广泛使用,调查其可能的副作用非常重要。
{"title":"Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Glomerulonephritis in a 15-year-old Patient After Receiving the Second Dose of the BBIBP-CorV (Sinopharm) COVID-19 Vaccine: A Case Report","authors":"Elham Ramezanzade, Reyhane Ghanbari, Tina Yazdanipour","doi":"10.5812/numonthly-127124","DOIUrl":"https://doi.org/10.5812/numonthly-127124","url":null,"abstract":"Introduction: Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of multisystemic autoimmune diseases that can involve organs such as kidneys and respiratory tracts. Since the initiation of COVID-19 vaccines, there have been few cases of antineutrophil cytoplasmic antibody (ANCA) glomerulonephritis development after receiving vaccine doses. Case Presentation: This report describes a 15-year-old man who has developed ANCA-associated glomerulonephritis (AAGN) after receiving the second dose of BBIBP-CorV (Sinopharm) COVID-19 vaccine. Conclusions: Development of AAGN after both natural SARS-CoV-2 infection and following other vaccinations raises the question of the possible causality between the two. Considering the widespread use of COVID-19 vaccines, it is highly important to investigate their possible side effects.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41748328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Montelukast as an Add-On Drug in Induced Azotemia in Humans Following Gastroenteritis 孟鲁司特作为一种附加药物治疗胃肠炎后诱发的人类氮血症
Q4 Medicine Pub Date : 2022-05-25 DOI: 10.5812/numonthly-123956
Farzane Moradi Shamami, P. Yousefichaijan, M. Hashemi, F. Dorreh, A. Arjmand, Saeed Karimi Matloub, M. Rezagholizamenjany
Background: Gastroenteritis, as a rare and heterogeneous condition, is characterized by patchy or diffuse infiltration of gastrointestinal tissue. Induced azotemia in humans following gastroenteritis has been evaluated in some studies. Objectives: The aim of the present study was to evaluate the effect of montelukast on induced azotemia in humans following gastroenteritis. Methods: This study examined children with gastroenteritis with moderate dehydration and more than 3 years of age. The cases had a glomerular filtration rate (GFR) of less than 90 and were evaluated in 2 groups of control (n = 20) and intervention (n = 20). Montelukast (5-mg tablets) was given to patients in the intervention group for 5 days. Normal saline at a rate of 20 cc/kg was given to both groups within 20 minutes until clinical symptoms improved. Finally, the improvement of renal function was evaluated and compared between the 2 groups using SPSS. Results: Out of 40 evaluated patients, the mean age of the control and intervention groups was 5.52 and 5.15 years, respectively. Also, 13 cases (65.0%) in the control group and 9 cases (45.0%) in the control group were males. The mean creatinine (Cr) was significantly reduced after treatment in the intervention group (P = 0.001). Also, the mean GFR after treatment was significantly higher in the intervention group (P = 0.001), and GFR improvement duration was significantly lower in the intervention group (P = 0.002). Conclusions: Montelukast as an add-on drug was effective in reducing the time of GFR enhancement; thus, we can consider it as an add-on drug in azotemia.
背景:胃肠炎是一种罕见且异质性的疾病,其特征是胃肠道组织的斑片状或弥漫性浸润。一些研究已经评估了肠胃炎后人类诱导氮质血症。目的:本研究的目的是评估孟鲁司特对肠胃炎后人类诱导氮血症的影响。方法:本研究调查了3岁以上中度脱水的胃肠炎患儿。患者肾小球滤过率(GFR)均小于90,分为对照组(n = 20)和干预组(n = 20)。干预组患者给予孟鲁司特5 mg片,疗程5天。两组均在20分钟内给予生理盐水20cc /kg,直至临床症状好转。最后用SPSS统计软件对两组患者肾功能改善情况进行评价和比较。结果:40例患者中,对照组和干预组的平均年龄分别为5.52岁和5.15岁。对照组男性13例(65.0%),对照组男性9例(45.0%)。干预组治疗后平均肌酐(Cr)显著降低(P = 0.001)。干预组治疗后GFR均值显著高于对照组(P = 0.001), GFR改善持续时间显著低于对照组(P = 0.002)。结论:孟鲁司特加药可有效缩短GFR增强时间;因此,我们可以将其视为氮血症的附加药物。
{"title":"Montelukast as an Add-On Drug in Induced Azotemia in Humans Following Gastroenteritis","authors":"Farzane Moradi Shamami, P. Yousefichaijan, M. Hashemi, F. Dorreh, A. Arjmand, Saeed Karimi Matloub, M. Rezagholizamenjany","doi":"10.5812/numonthly-123956","DOIUrl":"https://doi.org/10.5812/numonthly-123956","url":null,"abstract":"Background: Gastroenteritis, as a rare and heterogeneous condition, is characterized by patchy or diffuse infiltration of gastrointestinal tissue. Induced azotemia in humans following gastroenteritis has been evaluated in some studies. Objectives: The aim of the present study was to evaluate the effect of montelukast on induced azotemia in humans following gastroenteritis. Methods: This study examined children with gastroenteritis with moderate dehydration and more than 3 years of age. The cases had a glomerular filtration rate (GFR) of less than 90 and were evaluated in 2 groups of control (n = 20) and intervention (n = 20). Montelukast (5-mg tablets) was given to patients in the intervention group for 5 days. Normal saline at a rate of 20 cc/kg was given to both groups within 20 minutes until clinical symptoms improved. Finally, the improvement of renal function was evaluated and compared between the 2 groups using SPSS. Results: Out of 40 evaluated patients, the mean age of the control and intervention groups was 5.52 and 5.15 years, respectively. Also, 13 cases (65.0%) in the control group and 9 cases (45.0%) in the control group were males. The mean creatinine (Cr) was significantly reduced after treatment in the intervention group (P = 0.001). Also, the mean GFR after treatment was significantly higher in the intervention group (P = 0.001), and GFR improvement duration was significantly lower in the intervention group (P = 0.002). Conclusions: Montelukast as an add-on drug was effective in reducing the time of GFR enhancement; thus, we can consider it as an add-on drug in azotemia.","PeriodicalId":19466,"journal":{"name":"Nephro-urology Monthly","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48403748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Nephro-urology Monthly
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1